Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 3
2007 2
2010 1
2012 2
2013 3
2014 2
2015 3
2019 4
2020 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics.
Siegel M, Steiner G, Franssen LC, Carratu F, Herron J, Hartman K, Looney CM, Ducret A, Bray-French K, Rohr O, Hickling TP, Smith N, Marban-Doran C. Siegel M, et al. Among authors: hickling tp. Pharmaceutics. 2022 Dec 1;14(12):2672. doi: 10.3390/pharmaceutics14122672. Pharmaceutics. 2022. PMID: 36559166 Free PMC article.
HLAII peptide presentation of infliximab increases when complexed with TNF.
Casasola-LaMacchia A, Seward RJ, Tourdot S, Willetts M, Kruppa G, Agostino MJ, Bergeron G, Ahyi-Amendah N, Ciarla A, Lu Z, Kim HY, Hickling TP, Neubert H. Casasola-LaMacchia A, et al. Among authors: hickling tp. Front Immunol. 2022 Sep 13;13:932252. doi: 10.3389/fimmu.2022.932252. eCollection 2022. Front Immunol. 2022. PMID: 36177046 Free PMC article.
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
Hässler S, Bachelet D, Duhaze J, Szely N, Gleizes A, Hacein-Bey Abina S, Aktas O, Auer M, Avouac J, Birchler M, Bouhnik Y, Brocq O, Buck-Martin D, Cadiot G, Carbonnel F, Chowers Y, Comabella M, Derfuss T, De Vries N, Donnellan N, Doukani A, Guger M, Hartung HP, Kubala Havrdova E, Hemmer B, Huizinga T, Ingenhoven K, Hyldgaard-Jensen PE, Jury EC, Khalil M, Kieseier B, Laurén A, Lindberg R, Loercher A, Maggi E, Manson J, Mauri C, Mohand Oumoussa B, Montalban X, Nachury M, Nytrova P, Richez C, Ryner M, Sellebjerg F, Sievers C, Sikkema D, Soubrier M, Tourdot S, Trang C, Vultaggio A, Warnke C, Spindeldreher S, Dönnes P, Hickling TP, Hincelin Mery A, Allez M, Deisenhammer F, Fogdell-Hahn A, Mariette X, Pallardy M, Broët P; ABIRISK consortium. Hässler S, et al. Among authors: hickling tp. PLoS Med. 2020 Oct 30;17(10):e1003348. doi: 10.1371/journal.pmed.1003348. eCollection 2020 Oct. PLoS Med. 2020. PMID: 33125391 Free PMC article.
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins.
Kierzek AM, Hickling TP, Figueroa I, Kalvass JC, Nijsen M, Mohan K, Veldman GM, Yamada A, Sayama H, Yokoo S, Gulati A, Dhanikula RS, Gokemeijer J, Leil TA, Thalhauser CJ, Giorgi M, Swat MJ, Chelliah V, Small BG, Benson N, Walker M, Gadkar K, Quarmby V, Deng R, Ferrante A, Dickinson GL, Van Der Walt JS, Zhou L, Chen X, Jones HM, Narula J, Tourdot S, Lavé T, Ribba B, van der Graaf PH. Kierzek AM, et al. Among authors: hickling tp. CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):773-776. doi: 10.1002/psp4.12465. Epub 2019 Oct 8. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31529677 Free PMC article. No abstract available.
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.
Davda J, Declerck P, Hu-Lieskovan S, Hickling TP, Jacobs IA, Chou J, Salek-Ardakani S, Kraynov E. Davda J, et al. Among authors: hickling tp. J Immunother Cancer. 2019 Apr 15;7(1):105. doi: 10.1186/s40425-019-0586-0. J Immunother Cancer. 2019. PMID: 30992085 Free PMC article. Review.
26 results